Follow the Pundits

Tag: Baker Bros Advisors

Editorial illustration of scientist-investors analyzing biotech data with glowing tickers MDGL, BGNE, and INCY, representing Baker Bros’ science-driven investing strategy.

Madrigal, BeiGene, and Biotech Alpha: Inside the “Gene-ius” Kingmakers of Baker Bros. 2025

Biotech Jedi at work. Baker Bros’ 2025 victory lap shows how Madrigal, BeiGene, and ruthless conviction turned science into serious alpha.

Read entire article

Tags: ACAD, Acadia Pharma, Alkermes, ALKS, Baker Bros, Baker Bros Advisors, BeiGene, best hedge funds, BGNE, Biotech Investing, Concentrated Portfolios, featured-hedge-funds, FUNanc1al Edge, FUNanc1al Humor, FUNanc1al Investing, FunFund Index, Healthcare Innovation, Hedge Funds, hub-hedge, INCY, Incyte, INSM, Insmed, Long-Term Investing, Madrigal Pharmaceuticals, Market Leaders, MDGL, Revolution Medicines, RVMD
Baker Bros Are Bullish — Can Kodiak Kill the Bears?

Baker Bros Are Bullish — Can Kodiak Kill the Bears?

When the sharpest biotech investors on the planet deploy $60 million, it’s worth paying attention. Kodiak Sciences is a high-risk, high-reward retinal biotech with late-stage trials, real institutional backing, and binary outcomes ahead. Fun, factual, and unapologetically speculative.

Read entire article

Tags: Baker Bros, Baker Bros Advisors, Biotech Stocks, buy or sell KOD, Clinical stage biotech, featured-hedge-funds, funanc1al edge, funanc1al humor, funanc1al investing, FUNstock Index, Healthcare investing, hub-hedge, hub-insiders, Insider buying, KOD stock, Kodiak Sciences, Retinal disease, risks buying KOD, Speculative investing, why buy kod
Whimsical illustration of targeted protein degradation: glowing STAT6 protein being tagged with ubiquitin while a proteasome vacuum removes it; Baker Bros figures analyzing the process with excitement; biotech humor meets scientific innovation.

Biotech Investor Extraordinaire Baker Bros Adds to Its Massive Stake in Kymera. Should You Buy In?

Baker Bros — the Warren Buffetts of biotech — just super-sized their Kymera (KYMR) position. With Fast Track designation, jaw-dropping STAT6 trial results, and a pioneering protein-degradation platform, is KYMR becoming the next biotech legend?

Read entire article

Tags: Asthma therapeutics, Atopic Dermatitis, Baker Bros Advisors, Biotech Expertise, Biotech Investing, Biotech Stocks, Buy or sell KYMR, Clinical Trials, Fast Track FDA, featured-hedge-funds, Funanc1al Edge, FUNanc1al Humor, funanc1al investing, FUNstock Index, Hedge Fund Moves, hub-epiphany, hub-health, hub-hedge, hub-insiders, hub-techbio, Immunology, Insider Buying, Kymera stock, Kymera Therapeutics, KYMR, Risks Investing in KYMR, STAT6 degrader, Targeted Protein Degradation, why buy KYMR